UNTERNEHMENSDATEN
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate- …
KURSVERLAUF
1T
-1 %
1W
-2,3 %
1M
-1,1 %
6M
+23,7 %
YTD
+21,2 %
1J
+68,2 %
2J
+93,4 %
5J
+99,1 %
10J
–
FRAG DIE AGENTEN ZU PHVS
Keine Anlageberatung. Für die vollständige Analyse-Übersicht: zur Analyse-Seite →
ANALYSTEN-EINSCHÄTZUNG
KURSZIEL TIEF
42,00 $
KONSENS
53,80 $
MEDIAN
52,00 $
KURSZIEL HOCH
74,00 $
0
STRONG BUY
11
BUY
1
HOLD
0
SELL
0
STRONG SELL
12
GESAMT · Buy
| DATUM | ANALYSTENHAUS | RATING | AKTION |
|---|---|---|---|
| 25.06.2026 | Morgan Stanley | Overweight | maintain |
| 13.05.2026 | Citizens | Market Outperform | maintain |
| 07.04.2026 | Wedbush | Outperform | maintain |
| 06.04.2026 | RBC Capital | Outperform | maintain |
| 03.03.2026 | HC Wainwright & Co. | Buy | maintain |
| 04.12.2025 | Guggenheim | Buy | maintain |
| 04.12.2025 | Morgan Stanley | Overweight | maintain |
| 04.12.2025 | Oppenheimer | Outperform | maintain |
KENNZAHLEN
KGV
-10,43
KBV
8,15
EV/EBITDA
-10,89
EIGENKAPITALRENDITE
-16,9 %
NETTOMARGE
0 %
VERSCHULDUNG (D/E)
0
DIVIDENDENRENDITE
0 %
STAND
31.03.2026
FREE FLOAT & LIQUIDITÄT
STREUBESITZ
47,3 %
AKTIEN IM STREUBESITZ
33.053.634
Ø TAGESVOLUMEN (30T)
460.277
INVESTIERTE FONDS
| FONDS / INSTITUTION | ANTEILE | VERÄNDERUNG | STAND |
|---|---|---|---|
| Y-Intercept (Hong Kong) Ltd | 39.934 | +39.934 | 30.06.2026 |
| China Universal Asset Management Co., Ltd. | 14.719 | +3.352 | 30.06.2026 |
| Police & Firemen's Retirement System of New Jersey | 8.239 | +0 | 30.06.2026 |
| Mirae Asset Global Investments Co., Ltd. | 3.125 | -216 | 30.06.2026 |
| CoreCap Advisors, LLC | 2.700 | +2.700 | 30.06.2026 |
Keine Anlageberatung. Vergangene Wertentwicklung ist kein Indikator für zukünftige Ergebnisse.